Globus Medical downgraded by BofA Securities with a new price target
$GMED
Medical/Dental Instruments
Health Care
BofA Securities downgraded Globus Medical from Buy to Underperform and set a new price target of $63.00 from $83.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $97.00 | Underperform → Neutral | BofA Securities |
| 12/2/2024 | $83.00 → $100.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/7/2024 | $60.00 → $78.00 | Equal Weight → Overweight | Wells Fargo |
| 5/20/2024 | $60.00 → $80.00 | Neutral → Overweight | Piper Sandler |
| 3/18/2024 | $60.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 9/19/2023 | $61.00 | Hold → Buy | Stifel |
| 3/30/2023 | $67.00 | Hold → Buy | Canaccord Genuity |
BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00
Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously
Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously
CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain," said Dan Scavilla, president and CEO of Globus Medical. The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, andModulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system. The COHERE ™ ALIF Spacer is the latest addition to Globus Medical's Advanced Materials Science™ (AMS) implant portfolio, featuring proprietary porous surface technology designed for bone in-growth while maintaining the imaging and mechanical properties favored in a solid PEEK interbody spacer.1,2 "Porous
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
10-K - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share ("EPS") was $0.19 and non-GAAP diluted EPS was $0.84Non-GAAP adjusted EBITDA was $196.9 million, or 30.0% of net sales Full Year 2024: Worldwide net sales were $2,519.4 million, an increase of 60.6% on an as-reported basis a
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)